
Despite the elderly being the fastest-growing segment of the global population, only a few of their treatments have been clinically trialed in age-appropriate patients, with many of their therapies still not available in suitable formulations and dosages.
According to a new report from business intelligence provider GBI Research, many older people suffer from co-morbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of adverse drug events and hospitalization, with up to one third of elderly emergency admissions being drug-related.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze